Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGC · Real-Time Price · USD
12.97
-0.23 (-1.74%)
At close: Aug 1, 2025, 4:00 PM
12.83
-0.14 (-1.08%)
After-hours: Aug 1, 2025, 7:45 PM EDT

RGC Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2020
Selling, General & Admin
3.433.784.85.110.940.43
Upgrade
Research & Development
0.980.951.472.510.440.39
Upgrade
Operating Expenses
4.44.746.277.621.380.81
Upgrade
Operating Income
-4.4-4.74-6.27-7.62-1.38-0.81
Upgrade
EBT Excluding Unusual Items
-4.4-4.74-6.27-7.62-1.38-0.81
Upgrade
Other Unusual Items
0.370.370.210.020.03-
Upgrade
Pretax Income
-4.03-4.36-6.06-7.59-1.35-0.81
Upgrade
Earnings From Continuing Operations
-4.03-4.36-6.06-7.59-1.35-0.81
Upgrade
Minority Interest in Earnings
-0.060.060.190.15--
Upgrade
Net Income
-4.09-4.3-5.87-7.45-1.35-0.81
Upgrade
Net Income to Common
-4.09-4.3-5.87-7.45-1.35-0.81
Upgrade
Shares Outstanding (Basic)
494494494487380380
Upgrade
Shares Outstanding (Diluted)
494494494487380380
Upgrade
Shares Change (YoY)
--1.62%28.06%--
Upgrade
EPS (Basic)
-0.01-0.01-0.01-0.02-0.00-0.00
Upgrade
EPS (Diluted)
-0.01-0.01-0.01-0.02-0.00-0.00
Upgrade
Free Cash Flow
--4.01-4.99-6.05-0.77-0.84
Upgrade
Free Cash Flow Per Share
--0.01-0.01-0.01-0.00-0.00
Upgrade
EBITDA
-4.09-4.43-5.98-7.47-1.35-0.8
Upgrade
D&A For EBITDA
0.310.310.290.150.030.01
Upgrade
EBIT
-4.4-4.74-6.27-7.62-1.38-0.81
Upgrade
Advertising Expenses
-10.030.03--
Upgrade
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q